Effects of resveratrol supplementation on risk factors of non-communicable diseases: A meta-analysis of randomized controlled trials

References

• Andreadi, C., Britton, R. G., Patel, K. R. and Brown, K. (2014). Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy 10(3):524–525.
   PubMed Web of Science ®Google Scholar
• Anton, S. D., Embry, C., Marsiske, M., Lu, X., Doss, H., Leeuwenburgh, C. and Manini, T. M. (2014). Safety and metabolic outcomes of resveratrol supplementation in older adults: Results of a twelve-week, placebo-controlled pilot study. Exp. Gerontol. 57:181–187.
   PubMed Web of Science ®Google Scholar
• Bakker, G. C., van Erk, M. J., Pellis, L., Wopereis, S., Rubingh, C. M., Cnubben, N. H., Kooistra, T., Van, O. B. and Hendriks, H. F. (2010). An antiinflammatory dietary mix modulates inflammation and oxidative and metabolic stress in overweight men: A nutrigenomics approach. Am. J. Clin. Nutr. 91(4):1044–1059.
   PubMed Web of Science ®Google Scholar
• Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Alrasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M. and Ezhov, M. V. (2015). Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert. Opin. Drug. Saf. 11(1):1.
   Google Scholar
• Banach, M., Stulc, T., Dent, R. and Toth, P. P. (2016). Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int. J. Cardiol. 225:184–196.
   PubMed Web of Science ®Google Scholar
• Bashmakov, Y. K., Assaad-Khalil, S. H., Abou Seif, M., Udumyan, R., Megallaa, M., Rohoma, K. H., Zeitoun, M. and Petyaev, I. M. (2014). Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014:816307.
   PubMedGoogle Scholar
• Bhatt, J. K., Thomas, S. and Nanjan, M. J. (2012). Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 32(7):537–541.
   PubMed Web of Science ®Google Scholar
• Boocock, D. J., Patel, K. R., Faust, G. E. S., Normolle, D. P., Marczylo, T. H., Crowell, J. A., Brenner, D. E., Booth, T. D., Gescher, A. and Steward, W. P. (2007). Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B. 848(2):182–187.
   PubMed Web of Science ®Google Scholar
• Chachay, V. S., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore-Sullivan, T. M., Lee, P., Franklin, M., Klein, K., Taylor, P. J., Ferguson, M., Coombes, J. S., Thomas, G. P., Cowin, G. J., Kirkpatrick, C. M., Prins, J. B. and Hickman, I. J. (2014). Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12(12):2092–2103.
   PubMed Web of Science ®Google Scholar
• Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q. and Mi, M. (2015). Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial. Dig. Liver Dis. 47(3):226–232.
   PubMedGoogle Scholar
• Cottart, C. H., Nivet-Antoine, V. and Beaudeux, J. L. (2014). Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol. Nutr. Food Res. 58(1):7–21.
   PubMed Web of Science ®Google Scholar
• Cottart, C. H., Nivet-Antoine, V., Laguillier-Morizot, C. and Beaudeux, J. L. (2010). Resveratrol bioavailability and toxicity in humans. Mol. Nutr. Food Res. 54(1):7–16.
   PubMed Web of Science ®Google Scholar
• DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials. Control. Clin. Trials 7(3):177–188.
   PubMedGoogle Scholar
• Faghihzadeh, F., Adibi, P. and Hekmatdoost, A. (2015). The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: A randomised, double-blind, placebo-controlled study. Br. J. Nutr. 114(5):796–803.
   PubMed Web of Science ®Google Scholar
• Faghihzadeh, F., Adibi, P., Rafiei, R. and Hekmatdoost, A. (2014). Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr. Res. 34(10):837–843.
   PubMed Web of Science ®Google Scholar
• Ferrari, R. (1999). The Role of the in cardiovascular disease. Pharmacol. Res. 40(2):97–105.
   PubMed Web of Science ®Google Scholar
• Fiori, J. L., Shin, Y. K., Kim, W., Krzysik-Walker, S. M., Gonzalez-Mariscal, I., Carlson, O. D., Sanghvi, M., Moaddel, R., Farhang, K., Gadkaree, S. K., Doyle, M. E., Pearson, K. J., Mattison, J. A., de Cabo, R. and Egan, J. M. (2013). Resveratrol prevents beta-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 62(10):3500–3513.
   PubMed Web of Science ®Google Scholar
• Förstermann, U. and Sessa, W. C. (2011). Nitric oxide synthases: Regulation and function. Eur. Heart J. 33(7):264–269.
   PubMed Web of Science ®Google Scholar
• Fournier, A. and Safar, M. (2003). Age-specific relevance of usual blood pressure to vascular mortality. Lancet 361(9366):1903–1913.
   Google Scholar
• Freeman, D. J., Norrie, J., Caslake, M. J., Gaw, A., Ford, I., Lowe, G. D., O'Reilly, D. S., Packard, C. J. and Sattar, N. (2002). C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51(5):1596–1600.
   PubMed Web of Science ®Google Scholar
• Fujitaka, K., Otani, H., Jo, F., Jo, H., Nomura, E., Iwasaki, M., Nishikawa, M., Iwasaka, T. and Das, D. K. (2011). Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 31(11):842–847.
   PubMed Web of Science ®Google Scholar
• Furuta, T., Sugimoto, M., Yamade, M., Uotani, T., Shu, S., Ichikawa, H., Kagami, T., Iwaizumi, M., Yamada, T. and Osawa, S. (1995). The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J. Clin. Invest. 95(5):2021–2029.
   Web of Science ®Google Scholar
• Ghanim, H., Sia, C. L., Abuaysheh, S., Korzeniewski, K., Patnaik, P., Marumganti, A., Chaudhuri, A. and Dandona, P. (2010). An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J. Clin. Endocrinol. Metab. 95(9):E1–8.
   PubMed Web of Science ®Google Scholar
• Gliemann, L., Schmidt, J. F., Olesen, J., Biensø, R. S., Peronard, S. L., Grandjean, S. U., Mortensen, S. P., Nyberg, M., Bangsbo, J., Pilegaard, H. and Hellsten, Y. (2013). Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J. Physiol. 591(20):5047–5059.
   PubMed Web of Science ®Google Scholar
• Goh, K. P., Lee, H. Y., Lau, D. P., Supaat, W., Chan, Y. H. and Koh, A. F. (2014). Effects of resveratrol in patients with type 2 diabetes mellitus on skeletal muscle SIRT1 expression and energy expenditure. Int. J. Sport Nutr. Exerc. Metab. 24(1):2–13.
   PubMed Web of Science ®Google Scholar
• Gould, A. L., Davies, G. M., Alemao, E., Yin, D. D. and Cook, J. R. (2007). Cholesterol reduction yields clinical benefits: Meta-analysis including recent trials. Clin. Ther. 29(5):778–794.
   PubMed Web of Science ®Google Scholar
• Guo, X., Yang, B., Tan, J., Jiang, J. and Li, D. (2016). Associations of dietary intakes of anthocyanins and berry fruits with risk of type 2 diabetes mellitus: A systematic review and meta-analysis of prospective cohort studies. Eur. J. Clin. Nutr. 70(12):1360–1367.
   PubMed Web of Science ®Google Scholar
• Hausenblas, H. A., Schoulda, J. A. and Smoliga, J. M. (2015). Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus-systematic review and meta-analysis. Mol. Nutr. Food Res. 59(1):147–159.
   PubMed Web of Science ®Google Scholar
• Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjær Poulsen, M., Stødkilde-Jørgensen, H., Møller, H. J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S. and Grønbæk, H. (2016). Placebo-controlled, randomised clinical trial: High-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J. Gastroenterol. 51(4):456–463.
   PubMed Web of Science ®Google Scholar
• Higgins, JPT. and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available: http://www.cochrane-handbook.org. Accessed May 5, 2012.
   Google Scholar
• Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B. and Sinclair, D. A. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425(6954):191–196.
   PubMed Web of Science ®Google Scholar
• Jiang, W. J. (2008). Sirtuins: Novel targets for metabolic disease in drug development. Biochem. Bioph. Res. Co. 373(3):341–344.
   PubMed Web of Science ®Google Scholar
• Knekt, P., Kumpulainen, J., Järvinen, R., Rissanen, H., Heliövaara, M., Reunanen, A., Hakulinen, T. and Aromaa, A. (2002). Flavonoid intake and risk of chronic diseases. Am. J. Clin. Nutr. 76(3):560–568.
   PubMed Web of Science ®Google Scholar
• Kokil, G. R., Veedu, R. N., Ramm, G. A., Prins, J. B. and Parekh, H. S. (2015). Type 2 diabetes mellitus: Limitations of conventional therapies and intervention with nucleic acid-based therapeutics. Chem. Rev. 115(11):4719–4743.
   PubMed Web of Science ®Google Scholar
• Kolte, D., Aronow, W. S. and Banach, M. (2016). Polypills for the prevention of cardiovascular diseases. Expert Opin. Inv. Drugs 25(11):1.
   PubMed Web of Science ®Google Scholar
• Konno, H., Kanai, Y., Katagiri, M., Watanabe, T., Mori, A., Ikuta, T., Tani, H., Fukushima, S., Tatefuji, T. and Shirasawa, T. (2013). Melinjo (Gnetum gnemon L.) seed extract decreases serum uric acid levels in nonobese japanese males: A randomized controlled study. Evid-Based Compl. Alternat. Med. 2013:589169.
   PubMed Web of Science ®Google Scholar
• Kumar, B. J. and Joghee, N. M. (2013). Resveratrol supplementation in patients with type 2 diabetes mellitus: A prospective, open label, randomized controlled trial. Int. Res. J. Pharm. 4(8):245–249.
   Google Scholar
• Lei, J., Xuan, L., Bai, Y. Y., Li, S. H., Kai, S., Chen, H. and Hui, R. T. (2010). Short-term effect of cocoa product consumption on lipid profile: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 92(1):218–225.
   PubMed Web of Science ®Google Scholar
• Li, D. (2015). Omega-3 polyunsaturated fatty acids and non-communicable diseases: Meta-analysis based systematic review. Asia Pac. J. Clin. Nutr. 24(1):10–15.
   PubMed Web of Science ®Google Scholar
• Li, K., Huang, T., Zheng, J., Wu, K. and Li, D. (2014). Effect of Marine-derived n-3 polyunsaturated fatty acids on C-reactive protein, interleukin 6 and tumor necrosis factor α: A Meta-analysis. PLoS One 9(2):e88103.
   PubMed Web of Science ®Google Scholar
• Liu, K., Zhou, R., Wang, B. and Mi, M. T. (2014). Effect of resveratrol on glucose control and insulin sensitivity: A meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 99(6):1510–1519.
   PubMed Web of Science ®Google Scholar
• Liu, Y., Ma, W., Zhang, P., He, S. and Huang, D. (2015). Effect of resveratrol on blood pressure: A meta-analysis of randomized controlled trials. Clin. Nutr. 34(1):27–34.
   PubMed Web of Science ®Google Scholar
• Liu, Z., Song, Y., Zhang, X., Liu, Z., Zhang, W., Mao, W., Wang, W., Cui, W., Zhang, X. and Jia, X. (2005). Effects of trans -resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin. Exp. Pharmacol. P 32(12):1049–1054.
   PubMed Web of Science ®Google Scholar
• Macedo, R. C., Vieira, A., Marin, D. P. and Otton, R. (2015). Effects of chronic resveratrol supplementation in military firefighters undergo a physical fitness test–a placebo-controlled, double blind study. Chem. Biol. Interact. 227:89–95.
   PubMed Web of Science ®Google Scholar
• Magyar, K., Halmosi, R., Palfi, A., Feher, G., Czopf, L., Fulop, A., Battyany, I., Sumegi, B., Toth, K. and Szabados, E. (2012). Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 50(3):179–187.
   PubMed Web of Science ®Google Scholar
• Mendez-del Villar, M., Gonzalez-Ortiz, M., Martinez-Abundis, E., Perez-Rubio, K. G. and Lizarraga-Valdez, R. (2014). Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat Disord. 12(10):497–501.
   PubMed Web of Science ®Google Scholar
• Militaru, C., Donoiu, I., Craciun, A., Scorei, I. D., Bulearca, A. M. and Scorei, R. I. (2013). Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition 29(1):178–183.
   PubMed Web of Science ®Google Scholar
• Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P. and Klassen, T. P. (1998). Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128):609–613.
   PubMed Web of Science ®Google Scholar
• Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S. J., Yu, L., Kalantarhormozi, M., Rekabpour, S. J. and Netticadan, T. (2013). Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid-Based Compl. Alternat. Med. 2013:851267.
   PubMed Web of Science ®Google Scholar
• Movahed, A., Yu, L., Thandapilly, S. J., Louis, X. L. and Netticadan, T. (2012). Resveratrol protects adult cardiomyocytes against oxidative stress mediated cell injury. Arch. Biochem. Biophys. 527(2):74–80.
   PubMed Web of Science ®Google Scholar
• Ning, X., Daiber, A., Habermeier, A., Closs, E. I., Thum, T., Spanier, G., Lu, Q., Oelze, M., Torzewski, M. and Lackner, K. J. (2010). Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J. Pharmacol. Exp. Ther. 335(1):149–154.
   PubMed Web of Science ®Google Scholar
• Okamura, T. (2010). Dyslipidemia and cardiovascular disease: A series of epidemiologic studies in Japanese populations. J. Epidemiol. 20(4):259–265.
   PubMed Web of Science ®Google Scholar
• Patel, J., Martin, S. S. and Banach, M. (2016). Expert opinion: The therapeutic challenges faced by statin intolerance. Expert Opin. Pharmaco. 17(11):1497–1507.
   PubMed Web of Science ®Google Scholar
• Penumathsa, S. V., Thirunavukkarasu, M., Zhan, L., Maulik, G., Menon, V. P., Bagchi, D. and Maulik, N. (2010). Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell Mol. Med. 14(10):2539–2539.
   Web of Science ®Google Scholar
• Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stodkilde-Jorgensen, H., Moller, N., Jessen, N., Pedersen, S. B. and Jorgensen, J. O. (2013). High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 62(4):1186–1195.
   PubMed Web of Science ®Google Scholar
• Quiñones, M., Miguel, M. and Aleixandre, A. (2013). Beneficial effects of polyphenols on cardiovascular disease. Pharmacol. Res. 68(1):125–131.
   PubMed Web of Science ®Google Scholar
• Raj, P., Louis, X. L., Thandapilly, S. J., Movahed, A., Zieroth, S. and Netticadan, T. (2014). Potential of resveratrol in the treatment of heart failure. Life Sci. 95(2):63–71.
   PubMed Web of Science ®Google Scholar
• Ridker, P. M., Buring, J. E., Shih, J., Matias, M. and Hennekens, C. H. (1998). Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 98(8):731–733.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A. (2013). Effects of resveratrol supplementation on plasma lipids: A systematic review and meta-analysis of randomized controlled trials. Nutr. Rev. 71(12):822–835.
   PubMed Web of Science ®Google Scholar
• Sahebkar, A., Serban, C., Ursoniu, S., Wong, N. D., Muntner, P., Graham, I. M., Mikhailidis, D. P., Rizzo, M., Rysz, J., Sperling, L. S., Lip, G. Y. H. and Banach, M. (2015). Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors - Results from a systematic review and meta-analysis of randomized controlled trials. Int. J. Cardiol. 189(1):47–55.
   PubMedGoogle Scholar
• Sahebkar, A., Serban, M. C., Gluba-Brzózka, A., Mikhailidis, D. P., Cicero, A. F., Rysz, J. and Banach, M. (2016). Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition 32(11,12):1179.
   PubMed Web of Science ®Google Scholar
• Samsami-Kor, M., Daryani, N. E., Asl, P. R. and Hekmatdoost, A. (2015). Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: A randomized, Double-blind, Placebo-controlled Pilot Study. Arch. Med. Res. 46(4):280–285.
   PubMed Web of Science ®Google Scholar
• Schubert, S., Wowro, S., Tong, G., Berger, F. and Schmitt, K. (2011). Oral resveratrol therapy inhibits cancer-induced skeletal muscle and cardiac atrophy in vivo. Nutr. Cancer 63(5):749–762.
   PubMed Web of Science ®Google Scholar
• Singh, C. K., Ndiaye, M. A. and Ahmad, N. (2015). Resveratrol and cancer: Challenges for clinical translation. Biochim. Biophys. Acta. 1852(6):1178–1185.
   PubMed Web of Science ®Google Scholar
• Su, H. C., Hung, L. M. and Chen, J. K. (2006). Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 290(6):E1339–1346.
   PubMed Web of Science ®Google Scholar
• Sulaiman, M., Matta, M. J., Sunderesan, N. R., Gupta, M. P., Periasamy, M. and Gupta, M. (2010). Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol-Heart C 298(3):H833–H843.
   PubMed Web of Science ®Google Scholar
• Tanno, M. and Ayano, K. (2010). Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 285(285):8375–8382.
   PubMedGoogle Scholar
• Thazhath, S. S., Wu, T., Bound, M. J., Checklin, H. L., Standfield, S., Jones, K. L., Horowitz, M. and Rayner, C. K. (2016). Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: A randomized controlled trial. Am. J. Clin. Nutr. 103(1):66–70.
   PubMed Web of Science ®Google Scholar
• Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., Van De Weijer, T., Goossens, G. H., Hoeks, J., Van Der Krieken, S., Ryu, D., Kersten, S., Moonen-Kornips, E., Hesselink, M. K. C., Kunz, I., Schrauwen-Hinderling, V. B., Blaak, E. E., Auwerx, J. and Schrauwen, P. (2011). Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14(5):612–622.
   PubMed Web of Science ®Google Scholar
• Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Garcia-Almagro, F. J., Aviles-Plaza, F., Parra, S., Yanez-Gascon, M. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A. and Espin, J. C. (2012a). Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 56(5):810–821.
   PubMed Web of Science ®Google Scholar
• Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., Garcia-Almagro, F. J., Ruiz-Ros, J. A., Garcia-Conesa, M. T., Tomas-Barberan, F. A. and Espin, J. C. (2012b). One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 110(3):356–363.
   PubMed Web of Science ®Google Scholar
• Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., Yanez-Gascon, M. J., García-Almagro, F. J., Ruiz-Ros, J. A., Tomas-Barberan, F. A., Garcia-Conesa, M. T. and Espin, J. C. (2013). Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: A triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 27(1):37–48.
   PubMed Web of Science ®Google Scholar
• Walle, T., Hsieh, F., Delegge, M. H., Jr,  , O. J. and Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Meta Dispos. 32(12):1377–1382.
   PubMed Web of Science ®Google Scholar
• Wenzel, E. and Somoza, V. (2005). Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 49(5):472–481.
   PubMed Web of Science ®Google Scholar
• Witte, A. V., Kerti, L., Margulies, D. S. and Floel, A. (2014). Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 34(23):7862–7870.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2013). Global action plan for the prevention and control of noncommunicable diseases 2013–2020. World Health Organization, Geneva,
   Google Scholar
• World Health Organization. (2015). Cardiovascular Diseases (CVDs) Fact Sheet N°317. World Health Organization, Geneva.
   Google Scholar
• Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C., Kunz, I., Rossi Fanelli, F., Patterson, B. W. and Klein, S. (2012). Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 16(5):658–664.
   PubMed Web of Science ®Google Scholar
• Zortea, K., Franco, V. C., Francesconi, L. P., Cereser, K. M., Lobato, M. I. and Belmonte-de-Abreu, P. S. (2016). Resveratrol supplementation in schizophrenia patients: A randomized clinical trial evaluating serum glucose and cardiovascular risk factors. Nutrients 8(2):73.
   PubMed Web of Science ®Google Scholar